ADIL (Adial Pharmaceuticals) רווחיות מכירות לפי רווח נקי

Adial Pharmaceuticals (ADIL) is protected by patents in the field of alcoholism gene therapy, which minimizes pricing pressure. The net margin per unit of revenue confirms this resilience, where the value 0.00 describes the current level. Market capitalization is based on insurance company payouts for the drug AD04. Capital mobility is ensured by delegating trials to external CRO centers.
ADIL (Adial Pharmaceuticals, Inc.): פילוחים אנליטיים ודוחות לפי אינדיקטורים

Sales margin measures the share of net profit in revenue, revealing the actual operational efficiency between reporting periods. For Adial Pharmaceuticals (ADIL), this metric reflects the economics of outsourcing clinical trials to external CRO contractors. The current net profit margin stands at 0.00. This structure allows the biotech firm to minimize capital expenditures and avoid vendor risks. The stability of this metric confirms the resilience of the issuer's investment profile.